Ischemic Stroke Lab
Creating an integrated and cohesive brand strategy.
Background
The incidence of stroke has surpassed 800,000 cases each year, and acute stroke has become the leading cause of disability in the United States. Accurate etiology is a challenging, but a critical component of physician care for secondary stroke prevention. To address this dilemma, Ischemia Care responded by providing blood tests for cause of stroke, including a trial fibrillation, across the stroke care continuum, including point of care.
Challenge
As a new startup lab providing testing of RNA expression, Ischemia Care’s proprietary offering is made available through its lab division known as Ischemic Stroke Lab. The test is built upon significant peer reviewed published data, as well as other abstracts, presentations, white papers, etc. Due to the technological and advanced science involved, studies and clinical acceptance, the introduction of the company’s flagship product ISCDx, was only recently considered.
Solution
The agency rigorously researched the stroke and lab field discovering that increased demand being created by the aging American population, the demand for primary and comprehensive stroke centers – and the vascular neurologists (VNs) who lead them – is on the rise. This is especially true as the delivery of health care in the United States increasingly moves toward preventative, coordinated, population-based clinical care models operating within regional healthcare administrations. Due to such specialization, VNs total about 1,500 in the U.S. The agency developed and rolled out two websites: one for the corporation (https://ischemiacare.com/) and another for the product (https://ischemicstrokelab.com/). In one of the agency’s interviews with a leading neurologist, it was discovered that the one of the bigger parts of stroke workup is figuring out why people have a certain type of stroke. We heard many times that it is a bit mysterious. Baseline research confirmed our findings and the tagline “We take the mystery out of cryptogenic strokes” was accepted and rolled out across all channels.
Results
The company is gaining momentum and clinical trials will soon be finalized with several leading hospital groups. There is a growing consensus among VNs of the product and company.
Contact Us
Teleos Marketing: We Get Business™
1000 Forest Park Blvd, Suite 400
Fort Worth, TX 76110
817-769-6900
